Thromb Haemost 1975; 33(03): 606-609
DOI: 10.1055/s-0038-1647855
International Committee on Thrombosis and Haemostasis Task Force
Schattauer GmbH

Serologic Evidence for Hepatitis B Virus Infection in Patients with Hemophilia B[*]

A Multicenter Study
Jay H Hoofnagle
1   Division of Blood and Blood Products, Bureau of Biologics, Food and Drug Administration, 8800 Rockville Pike, Bethesda, Maryland, 20014, U.S.A.
2   University of North Carolina Medical School, Chapel Hill, North Carolina, U.S.A.
,
David Aronson
1   Division of Blood and Blood Products, Bureau of Biologics, Food and Drug Administration, 8800 Rockville Pike, Bethesda, Maryland, 20014, U.S.A.
2   University of North Carolina Medical School, Chapel Hill, North Carolina, U.S.A.
,
Harold Roberts
1   Division of Blood and Blood Products, Bureau of Biologics, Food and Drug Administration, 8800 Rockville Pike, Bethesda, Maryland, 20014, U.S.A.
2   University of North Carolina Medical School, Chapel Hill, North Carolina, U.S.A.
› Author Affiliations
Further Information

Publication History

Received 30 January 1975

accepted 30 January 1975

Publication Date:
02 July 2018 (online)

Summary

Among sera from 160 patients with hemophilia B from 9 centers in Europe and North and South America, 2.5% were positive for hepatitis B surface antigen (HBsAg), 60% for antibody to HBsAg, and 31% for antibody to the hepatitis B core antigen. Evidence of exposure to the hepatitis B virus appeared to be related to severity of disease and age rather than the source and method of manufacturer of factor IX concentrate.

* Task Force Report


 
  • References

  • 1 Barker L. F, Hoofnagle J. H. Transmission of viral hepatitis, type B, by plasma derivatives. 13th International Congress of IABS Budapest. . 1973
  • 2 Boklan B. F. Factor IX concentrate and viral hepatitis. Annals of Internal Medicine 1971; 74: 298
  • 3 Gocke D. J, Howe C. Rapid detection of Australia antigen by counterelectrophoresis. Journal of Immunology 1970; 104: 1031
  • 4 Hoofnagle J. H, Gerety R. J, Barker L. F. Antibody to hepatitis B virus core in man. Lancet 1973; ii: 869
  • 5 Kasper C. K, Kipnis S. A. Hepatitis and clotting-factor concentrates. Journal of the American Medical Association 1972; 221: 510
  • 6 Ling C. M, Overby L. R. Prevalence of hepatitis B virus antigen as revealed by direct radioimmune assay with 125-I antibody. Journal of Immunology 1972; 109: 834
  • 7 Prince A. M, Brotman B, Jass D, Ikram M. Specificity of the direct solid-phase radioimmunoassay for the detection of hepatitis-B-antigen. Lancet i: 1346 1973;
  • 8 Vyas G. N, Shulman N. R. Hemagglutination assay for antigen and antibody associated with viral hepatitis. Science 1970; 170: 332